Zur Kurzanzeige

dc.contributor.authorAldred, Jason
dc.contributor.authorAnca-Herschkovitsch, Marieta
dc.contributor.authorAntonini, Angelo
dc.contributor.authorBajenaru, Ovidiu
dc.contributor.authorBourgeois, Paul
dc.contributor.authorCubo Delgado, Esther 
dc.contributor.authorDavis, Thomas L.
dc.contributor.authorIansek, Robert
dc.contributor.authorKovács, Norbert
dc.contributor.authorKukreja, Pavnit
dc.contributor.authorOnuk, Koray
dc.contributor.authorPontieri, Francesco E.
dc.contributor.authorRobieson, Weining
dc.contributor.authorSiddiqui, Mustafa S.
dc.contributor.authorSimu, Mihaela
dc.contributor.authorStandaert, David G.
dc.contributor.authorChaudhuri, K. Ray
dc.date.accessioned2024-03-11T11:15:23Z
dc.date.available2024-03-11T11:15:23Z
dc.date.issued2020-09
dc.identifier.issn1758-2024
dc.identifier.urihttp://hdl.handle.net/10259/8797
dc.description.abstractAim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the ‘5-2-1 criteria’ (≥five-times daily oral levodopa use, ≥two daily hours with ‘Off’ symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson’s disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD – a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) – is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa–carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment.en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherFuture Medicineen
dc.relation.ispartofNeurodegenerative Disease Management. 2020, V. 10, n. 5, p. 309-323en
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject5-2-1es
dc.subjectCriteria for advanced PDen
dc.subjectDyskinesiaen
dc.subjectLCIGen
dc.subjectLevodopaen
dc.subjectLevodopa-carbidopa intestinal gelen
dc.subjectOff timeen
dc.subjectParkinson’s diseaseen
dc.subject.otherSistema nervioso-Enfermedadeses
dc.subject.otherNervous system-Diseasesen
dc.subject.otherMedicinaes
dc.subject.otherMedicineen
dc.subject.otherNeurologíaes
dc.subject.otherNeurologyen
dc.titleApplication of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBEen
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://doi.org/10.2217/nmt-2020-0021es
dc.identifier.doi10.2217/nmt-2020-0021
dc.identifier.essn1758-2032
dc.journal.titleNeurodegenerative Disease Managementen
dc.volume.number10es
dc.issue.number5es
dc.page.initial309es
dc.page.final323es
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige